[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200804868B - Anti-OX40L antibodies and methods using same - Google Patents

Anti-OX40L antibodies and methods using same

Info

Publication number
ZA200804868B
ZA200804868B ZA200804868A ZA200804868A ZA200804868B ZA 200804868 B ZA200804868 B ZA 200804868B ZA 200804868 A ZA200804868 A ZA 200804868A ZA 200804868 A ZA200804868 A ZA 200804868A ZA 200804868 B ZA200804868 B ZA 200804868B
Authority
ZA
South Africa
Prior art keywords
methods
same
ox40l antibodies
ox40l
antibodies
Prior art date
Application number
ZA200804868A
Other languages
English (en)
Inventor
Martin Flavius
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA200804868B publication Critical patent/ZA200804868B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200804868A 2005-12-16 2006-12-15 Anti-OX40L antibodies and methods using same ZA200804868B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75137705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
ZA200804868B true ZA200804868B (en) 2009-10-28

Family

ID=38616368

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804868A ZA200804868B (en) 2005-12-16 2006-12-15 Anti-OX40L antibodies and methods using same

Country Status (18)

Country Link
US (2) US7812133B2 (xx)
EP (1) EP1973949A2 (xx)
JP (1) JP2009519718A (xx)
KR (1) KR20080080639A (xx)
CN (1) CN101374865A (xx)
AR (1) AR057253A1 (xx)
AU (1) AU2006343459A1 (xx)
BR (1) BRPI0621065A2 (xx)
CA (1) CA2633602A1 (xx)
CR (1) CR10069A (xx)
EC (1) ECSP088543A (xx)
IL (1) IL191820A0 (xx)
MA (1) MA30153B1 (xx)
NO (1) NO20083147L (xx)
RU (1) RU2426744C2 (xx)
TW (1) TW200732349A (xx)
WO (1) WO2007133290A2 (xx)
ZA (1) ZA200804868B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
EP2041756B1 (en) 2006-07-14 2015-05-13 FEI Company A multi-source plasma focused ion beam system
JP2010518873A (ja) * 2007-02-27 2010-06-03 ジェネンテック, インコーポレイテッド アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US20120020960A1 (en) * 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
CN103221427B (zh) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 抗ox40抗体和使用其的方法
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EA030851B1 (ru) 2011-04-21 2018-10-31 Бристол-Майерс Сквибб Компани Полипептиды антитела, которые антагонизируют cd40
RU2562874C1 (ru) * 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против ох40 и способы их применения
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017165652A (ja) * 2014-06-30 2017-09-21 国立大学法人東北大学 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬
EP3194445A4 (en) * 2014-08-04 2018-05-23 Baylor Research Institute Antagonistic anti-ox40l antibodies and methods of their use
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
CA2968642A1 (en) * 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) * 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
DK3265117T3 (da) 2015-03-06 2021-02-08 Canimguide Therapeutics Ab Immunsystemmodulatorer og præparater
CN108137686B (zh) 2015-05-07 2022-06-17 阿吉纳斯公司 抗ox40抗体及其使用方法
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
US11065301B2 (en) 2016-04-15 2021-07-20 Pontificia Universidad Catolica De Chile Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019100320A1 (en) 2017-11-24 2019-05-31 Eucure (Beijing) Biopharma Co., Ltd Anti-ox40 antibodies and uses thereof
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
TW202330023A (zh) * 2021-08-10 2023-08-01 英商科馬布有限公司 異位性皮膚炎之治療
IL314314A (en) * 2022-02-09 2024-09-01 Petmedix Ltd Therapeutic antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) * 1997-09-25 2007-05-16 武田薬品工業株式会社 gp34結合阻害物を有効成分として含有する医薬組成物
WO2001094586A2 (en) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
FR2822846B1 (fr) * 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
JP3926596B2 (ja) 2001-09-28 2007-06-06 独立行政法人科学技術振興機構 Ox40l遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
WO2003059245A2 (en) * 2001-12-18 2003-07-24 J & J Research Pty Ltd Method of treating asthma
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
CA2496795C (en) 2002-08-28 2014-06-03 Paul B. Burton Compositions and methods for treating cardiovascular disease
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
JP2006081061A (ja) * 2004-09-13 2006-03-23 Alpine Electronics Inc 音声出力装置及び音声/映像出力装置
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
JP2010518873A (ja) 2007-02-27 2010-06-03 ジェネンテック, インコーポレイテッド アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用

Also Published As

Publication number Publication date
TW200732349A (en) 2007-09-01
BRPI0621065A2 (pt) 2011-11-29
ECSP088543A (es) 2008-07-30
US7812133B2 (en) 2010-10-12
WO2007133290A3 (en) 2008-01-10
CA2633602A1 (en) 2007-11-22
AR057253A1 (es) 2007-11-21
NO20083147L (no) 2008-09-16
US20090053230A1 (en) 2009-02-26
KR20080080639A (ko) 2008-09-04
US20100272738A1 (en) 2010-10-28
MA30153B1 (fr) 2009-01-02
WO2007133290A8 (en) 2008-03-27
CR10069A (es) 2008-10-10
AU2006343459A1 (en) 2007-11-22
JP2009519718A (ja) 2009-05-21
RU2008129111A (ru) 2010-01-27
CN101374865A (zh) 2009-02-25
EP1973949A2 (en) 2008-10-01
RU2426744C2 (ru) 2011-08-20
WO2007133290A2 (en) 2007-11-22
IL191820A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
IL272883A (en) Monoclonal antibodies and their uses
ZA200804868B (en) Anti-OX40L antibodies and methods using same
IL222922A (en) Antibodies against neurophilin-1 and their use
HK1133441A1 (en) Anti-mn antibodies and methods of using same
SI1973950T1 (sl) Anti-EphB4 protitelesa in postopki njihove uporabe
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL184024A0 (en) Irta-5 antibodies and their uses
EP1915177A4 (en) ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
IL178277A0 (en) Irta-5 antibodies and their uses
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
EP1846032A4 (en) LUCA2 AND ANTIBODY BINDING
HK1107402A1 (en) Kid31 and antibodies that bind thereto kid31
IL231891A (en) Anti-ephrinb2 antibodies and methods for their use
EP1765396A4 (en) ANTIBODY
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
GB0420466D0 (en) Anti-glucan antibodies
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
ZA200702281B (en) IRTA-4 antibodies and their uses
GB0505620D0 (en) Methods and materials therefor
ZA200705716B (en) IRTA-2 antibodies and their uses
GB0507219D0 (en) Antibody and uses thereof
GB0507272D0 (en) Antibody and uses thereof
GB0518875D0 (en) Methods and means